These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 11703398

  • 1. Cerebrovascular dysfunction after subarachnoid haemorrhage: novel mechanisms and directions for therapy.
    Sobey CG.
    Clin Exp Pharmacol Physiol; 2001 Nov; 28(11):926-9. PubMed ID: 11703398
    [Abstract] [Full Text] [Related]

  • 2. Subarachnoid haemorrhage: what happens to the cerebral arteries?
    Sobey CG, Faraci FM.
    Clin Exp Pharmacol Physiol; 1998 Nov; 25(11):867-76. PubMed ID: 9807657
    [Abstract] [Full Text] [Related]

  • 3. Type V phosphodiesterase expression in cerebral arteries with vasospasm after subarachnoid hemorrhage in a canine model.
    Inoha S, Inamura T, Ikezaki K, Nakamizo A, Amano T, Fukui M.
    Neurol Res; 2002 Sep; 24(6):607-12. PubMed ID: 12238630
    [Abstract] [Full Text] [Related]

  • 4. Impaired cerebral vasodilator responses to NO and PDE V inhibition after subarachnoid hemorrhage.
    Sobey CG, Quan L.
    Am J Physiol; 1999 Nov; 277(5):H1718-24. PubMed ID: 10564124
    [Abstract] [Full Text] [Related]

  • 5. An overview of new pharmacological treatments for cerebrovascular dysfunction after experimental subarachnoid hemorrhage.
    Grasso G.
    Brain Res Brain Res Rev; 2004 Jan; 44(1):49-63. PubMed ID: 14739002
    [Abstract] [Full Text] [Related]

  • 6. Systemic administration of phosphodiesterase V inhibitor, sildenafil citrate, for attenuation of cerebral vasospasm after experimental subarachnoid hemorrhage.
    Atalay B, Caner H, Cekinmez M, Ozen O, Celasun B, Altinors N.
    Neurosurgery; 2006 Nov; 59(5):1102-7; discussion 1107-8. PubMed ID: 17143244
    [Abstract] [Full Text] [Related]

  • 7. Effects of nitroglycerin on vasospasm and cyclic nucleotides in a primate model of subarachnoid hemorrhage.
    Nakao K, Murata H, Kanamaru K, Waga S.
    Stroke; 1996 Oct; 27(10):1882-7; discussion 1887-8. PubMed ID: 8841348
    [Abstract] [Full Text] [Related]

  • 8. Prevention of cerebral vasospasm by local delivery of cromakalim with a biodegradable controlled-release system in a rat model of subarachnoid hemorrhage.
    Omeis I, Chen W, Jhanwar-Uniyal M, Rozental R, Murali R, Abrahams JM.
    J Neurosurg; 2009 May; 110(5):1015-20. PubMed ID: 19119878
    [Abstract] [Full Text] [Related]

  • 9. Potassium-channel openers KMUP-1 and pinacidil prevent subarachnoid hemorrhage-induced vasospasm by restoring the BKCa-channel activity.
    Chen JY, Cheng KI, Tsai YL, Hong YR, Howng SL, Kwan AL, Chen IJ, Wu BN.
    Shock; 2012 Aug; 38(2):203-12. PubMed ID: 22576001
    [Abstract] [Full Text] [Related]

  • 10. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
    Willette RN, Shiloh AO, Sauermelch CF, Sulpizio A, Michell MP, Cieslinski LB, Torphy TJ, Ohlstein EH.
    J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501
    [Abstract] [Full Text] [Related]

  • 11. The role of nitric oxide in resolution of vasospasam corresponding with cerebral vasospasms after subarachnoid haemorrhage: animal model.
    Dizdarević K.
    Bosn J Basic Med Sci; 2008 May; 8(2):177-82. PubMed ID: 18498271
    [Abstract] [Full Text] [Related]

  • 12. Effects of subarachnoid hemorrhage on vascular responses to calcitonin gene-related peptide and its related second messengers.
    Sutter B, Suzuki S, Arthur AS, Kassell NF, Lee KS.
    J Neurosurg; 1995 Sep; 83(3):516-21. PubMed ID: 7666231
    [Abstract] [Full Text] [Related]

  • 13. Dysfunction of nitric oxide synthases as a cause and therapeutic target in delayed cerebral vasospasm after SAH.
    Pluta RM.
    Neurol Res; 2006 Oct; 28(7):730-7. PubMed ID: 17164036
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance.
    Kim D, Rybalkin SD, Pi X, Wang Y, Zhang C, Munzel T, Beavo JA, Berk BC, Yan C.
    Circulation; 2001 Nov 06; 104(19):2338-43. PubMed ID: 11696475
    [Abstract] [Full Text] [Related]

  • 16. Sildenafil increases cerebrovascular reactivity: a transcranial Doppler study.
    Brenner S.
    Neurology; 2006 May 09; 66(9):1455-6; author reply 1455-6. PubMed ID: 16682690
    [No Abstract] [Full Text] [Related]

  • 17. Levosimendan, a new therapeutic approach to prevent delayed cerebral vasospasm after subarachnoid hemorrhage?
    Konczalla J, Wanderer S, Mrosek J, Gueresir E, Schuss P, Platz J, Seifert V, Vatter H.
    Acta Neurochir (Wien); 2016 Nov 09; 158(11):2075-2083. PubMed ID: 27614436
    [Abstract] [Full Text] [Related]

  • 18. A hypothesis on possible neurochemical mechanisms of action of cervical spinal cord stimulation in prevention and treatment of cerebral arterial vasospasm after aneurysmal subarachnoid hemorrhage.
    Yin D, Slavin KV.
    Med Hypotheses; 2015 Sep 09; 85(3):355-8. PubMed ID: 26141634
    [Abstract] [Full Text] [Related]

  • 19. A new approach to the treatment of cerebral vasospasm: the angiographic effects of tadalafil on experimental vasospasm.
    Koktekir E, Erdem Y, Akif Bayar M, Gokcek C, Karatay M, Kilic C.
    Acta Neurochir (Wien); 2010 Mar 09; 152(3):463-9. PubMed ID: 19841856
    [Abstract] [Full Text] [Related]

  • 20. Multifaceted effects of selective inhibitor of phosphodiesterase III, cilostazol, for cerebral vasospasm after subarachnoid hemorrhage in a dog model.
    Yamaguchi-Okada M, Nishizawa S, Mizutani A, Namba H.
    Cerebrovasc Dis; 2009 Mar 09; 28(2):135-42. PubMed ID: 19506373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.